99% of administered nanoparticles will accumulate and sequester in the liver after
administration into the body. This results in reduced delivery to the targeted diseased tissue …

Nanoparticles that respond to internal and external stimuli to carry out controlled release of
anticancer drugs have been developed. In this review, we focus on the development of …

Nanocarriers, due to their unique features, are of increased interest among researchers
working with pharmaceutical formulations. Polymeric nanoparticles and nanocapsules …

Recruitment of inflammatory cells to tumor has been well documented, with the most
frequent inhabitants being macrophages termed as tumor associated macrophages,(TAMs) …

Immunotherapeutic nanoparticles (NPs) could be a viable option for delivering cytotoxic
agents in a manner which suppresses their toxic manifestations. Doxorubicin (DOX) loaded …

Ligand-mediated polymeric micelles have enormous potential for improving the efficacy of
glioma therapy. Linear–dendritic drug–polymer conjugates composed of doxorubicin (DOX) …

Lung cancer is one of the most chronic forms of cancer that causes cancer-related mortality
globally. The current treatment therapy includes chemotherapy, radiation/bio therapy, and …

Since the development of supramolecular chemical biology, self‐organised nano‐
architectures have been widely explored in a variety of biomedical applications …

One of the most significant barriers to the clinical transformation of nanomedicines is low
drug distribution in solid tumors due to quick clearance of nanomedicine after injection …

Development of nanosized drug delivery systems in cancer therapy is directed toward
improving tumor selectivity and minimizing damages of healthy tissue. We introduce a …